文献速递衰弱、肌少症与跌倒老年综合评估

基于代谢组学鉴定与验证肌酸前体胍基乙酸用于老年人衰弱

Metabolomics-based identification and validation of the creatine precursor guanidinoacetic acid for frailty in older adults.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

研究在福建前瞻性老龄化队列2265名60岁及以上社区人群中分析血浆代谢物,发现胍基乙酸(GAA)是与衰弱关联最强的候选标志物,横断面验证AUC为0.670;GAA水平较高与衰弱及衰弱前期风险降低相关,并预测3年衰弱指数轨迹进展可能性更低。

要点

  • GAA被鉴定为与衰弱关联最强的血浆代谢标志物,横断面验证AUC=0.670。
  • GAA最高四分位者衰弱前期OR=0.46、衰弱OR=0.15(均P<.001)。
  • GAA最高四分位者3年衰弱指数中高轨迹风险分别降低36%和66%。

核心结论

  • GAA是潜在的衰弱代谢生物标志物,较高GAA水平与较低衰弱风险及较低衰弱进展可能性相关。

研究设计与样本

  • 基于福建前瞻性老龄化队列(ChiCTR 2000032949),2020年纳入2265名60岁及以上社区居住个体。
  • 采用超高效液相色谱-串联质谱(UPLC-MS/MS)分析血浆代谢物,衰弱用Fried表型和衰弱指数评估。

主要发现

  • 广泛靶向代谢组学分析鉴定出889种代谢物,ROC分析将GAA列为与衰弱关联最强的候选标志物。
  • 大型横断面队列(N=1972)验证GAA较低者衰弱患病率较高(P<.001)。
  • 多分类逻辑回归显示GAA最高四分位与衰弱前期和衰弱风险降低相关,OR分别为0.46(95%CI:0.32-0.66)和0.15(95%CI:0.07-0.33),均P<.001。
  • 3年随访中基于组的轨迹模型识别出三种衰弱指数轨迹:低上升型59.6%、中上升型34.1%、高上升型6.3%。
  • GAA最高四分位者追随中上升型和高上升型衰弱指数轨迹的可能性分别降低36%和66%(P=.016和P=.022)。

关键数值与推荐

  • 横断面验证GAA识别衰弱的AUC=0.670。
  • GAA最高四分位与衰弱前期OR=0.46(95%CI:0.32-0.66)、衰弱OR=0.15(95%CI:0.07-0.33),均P<.001。
  • GAA最高四分位与中上升型衰弱指数轨迹关联P=.016,与高上升型轨迹关联P=.022。

临床怎么用

  • GAA可作为社区老年人衰弱风险分层与进展预测的候选代谢标志物,但尚需外部验证后方可用于临床决策。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subtle biological changes related to frailty may be undetected by standard clinical methods, and reliable biomarkers for frailty are still under investigation. This study was conducted to profile plasma metabolite patterns associated with frailty and validate the most significant metabolite for identifying and predicting frailty in cross-sectional and longitudinal analyses. METHODS: The "Fujian Prospective Aging Cohort" (ChiCTR 2000032949) enrolled 2,265 community-dwelling individuals aged 60 and above in 2020. Plasma metabolites were analyzed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Frailty was assessed using Fried's phenotype and the Frailty Index. RESULTS: Widely targeted metabolomic analysis identified 889 metabolites. GAA was identified as the top frailty-associated candidate by ROC analysis and validated in a large cross-sectional cohort (AUC = 0.670). This cohort (N = 1,972) confirmed that subjects with lower GAA levels had a higher prevalence of frailty (P < .001). Multinomial logistic regression showed that higher GAA levels were significantly associated with lower odds of prefrailty and frailty; the ORs were 0.46 (95% CI: 0.32-0.66), and 0.15 (95% CI: 0.07-0.33) in the highest quartile, both P < .001). Over a 3-year follow-up period, a group-based trajectory model identified three Frailty Index trajectories: low-elevated (59.6%), moderate-elevated (34.1%), and high-elevated (6.3%). Subjects in the highest GAA quartile had a 36% and 66% lower likelihood of following moderate-elevated and high-elevated Frailty Index trajectories (P = .016 and P = .022). CONCLUSIONS: This study identifies GAA as a potential metabolic biomarker for frailty. Higher GAA levels are associated with lower frailty odds and provide predictive value for a lower likelihood of frailty progression.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Huang X, Lin S, et al. Metabolomics-based identification and validation of the creatine precursor guanidinoacetic acid for frailty in older adults. J Gerontol A Biol Sci Med Sci. 2025. PMID: 40498546. doi:10.1093/gerona/glaf127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。